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Mitochondria are fascinating organelles, which fulﬁll multiple cellular functions, as diverse as energy production, fatty acid β
oxidation, reactive oxygen species (ROS) production and detoxiﬁcation, and cell death regulation. The coordination of these
functions relies on autonomous mitochondrial processes as well as on sustained cross-talk with other organelles and/or the
cytosol. Therefore, this implies a tight regulation of mitochondrial functions to ensure cell homeostasis. In many diseases (e.g.,
cancer, cardiopathies, nonalcoholic fatty liver diseases, and neurodegenerative diseases), mitochondria can receive harmful signals,
dysfunction and then, participate to pathogenesis. They can undergo either a decrease of their bioenergetic function or a process
called mitochondrial permeability transition (MPT) that can coordinate cell death execution. Many studies present evidence that
protectionofmitochondrialimitsdiseaseprogressionandseverity.Here,wewillreviewrecent strategiestopreservemitochondrial
functions via direct or indirect mechanisms of MPT inhibition. Thus, several mitochondrial proteins may be considered for
cytoprotective-targeted therapies.
1.Introduction
Mitochondria are intracellular organelles, whose ﬁrst discov-
ered function is energy production by oxidative phosphory-
lation [1]. Depending on the mammalian tissue, mitochon-
dria may have additional functions, such as β oxidation, heat
production, reactive oxygen species (ROS) metabolism, and
cell death coordination. However, since the emergence of the
concept of mitochondrial control of cell death in the 95’s (for
recent reviews: [2, 3]), it became evident that mitochondria
participate to various types of cell death, that are, apoptosis,
necrosis, oncosis and mitotic catastrophy via mitochondrial
membranepermeabilization(MMP),releaseofproapoptotic
factors contained in the intermembrane space to the cytosol
and possibly ﬁssion, even if mitochondrial fragmentation is
not suﬃcient perse to induce cell death [4, 5]. Mitochondrial
dysfunction has been associated with a series of human
diseasessuchascancer,cardiopathies,nonalcoholicfattyliver
diseases, neurodegenerative diseases, and aging. When due
to genetic dysfunction, the diseases have been systematically
characterized in animal models [6, 7]. Thus, mitochondrial
impairment can be linked either to the metabolic function of
these organelles, their role in cell death, or both. In addition,
in chronic pathologies, such as cardiac volume overload-
induced hypertrophy [8], mitochondrial dysfunction pre-
cedes cell loss by apoptosis and necrosis, meaning that both
dysfunctions can be separated chronologically during the
progression of the disease. This is also observed in the patho-
genesis of nonalcoholic steatohepatitis, whatever its initial
cause, as extensively reviewed [9]. Hepatic mitochondrial
dysfunction would lead to apoptosis or necrosis depending
on the energy status of the cell [9].
Metabolic impairment manifests by decreased ATP syn-
thesis capacity, enhanced ROS production due to electron
leak from the respiratory chain, change in intracellular
pH and frequently, by morphological alterations of mito-
chondrial network. For instance, heart failure which is
deﬁned as the inability of the heart to keep up with the
demands and to provide adequate blood ﬂow to other
organs such as the brain, liver, and kidneys is accompanied2 Biochemistry Research International
by a decrease in energy production and energy transfer
capacity [10]. This leads to a decrease in energy charge of
the myocardium that has been described as a prognostic
factor in dilated cardiomyopathies [11]. This metabolic
impairment also aﬀects the peripheric circulation and
was shown to involve decreased mitochondrial biogenesis
[10].
MMP corresponds to multiple events that irreversibly
leadtocelldeath[2,12].Theselethaleventsarenonexclusive,
some of them can occur independently, whereas others are
intimately linked. Thus, MMP refers to protein translocation
from cytosol to outer membrane (OM), rupture of outer
mitochondrial membrane, loss of inner membrane potential
(ΔΨm), cristae remodeling and release of intermembrane
space proteins such as cytochrome c or apoptosis-inducing
factor (AIF). For instance, upon various stress, Bax or tBid,
which reside in the cytosol, can translocate to mitochondrial
membranes, oligomerize with mitochondrial proteins to
form large channels allowing cytochrome c release and
activation of the intrinsic apoptosis signaling cascade (for
review: [2]).
In many pathophysiological models, but not all, MMP
also involves the so-called opening of the permeability tran-
sition pore complex (PTPC), which mediates a nonselective
permeabilization of the IM and OM to molecules of molec-
ular mass (MM) under 1.5kDa (see below for more details)
[2, 12]. Thus, in chemotherapy-treated tumor cell lines and
ischemic neuronal cells, Bax can interact with the adenine
nucleotide translocase (ANT) and/or the voltage-dependent
anion channel (VDAC) to promote MMP and cell death.
Here, we will review direct and indirect mechanisms
or means to protect mitochondrial functions via a closure
of PTPC and a prevention of mitochondrial permeability
transition (MPT). The discussion of MPT regulatory mech-
anisms will be based on selected articles focusing on heart
diseases and cancer.
2. Mitochondrial Membrane
PermeabilityandPTPC
Mitochondrial membrane permeability is strictly controlled
in unicellular and multicellular organisms harboring these
organelles. The OM is believed to be freely permeable to
ionsandmetabolitesviaentrythroughproteinchannels(e.g.,
voltage-dependentanionchannel,VDAC),whereastheinner
membrane (IM) is considered as impermeable. Thus, the
entry and exit of ions or metabolites trough the IM are
mediated by integral proteins such as the members of the
mitochondrial carrier family [13]. The prototypic protein of
this family is ANT or ADP/ATP carrier, which mediates the
stoichiometricexchangeofADPandATPbetweenthematrix
and the intermembrane space [14]. Moreover, osmotic
movements of water accompany solutes transport from
cytosol to matrix, but the molecular basis of these transports
is still largely unknown [15]. When excessive stimulation by
endogenoussignals(excessiveROS,calcium(Ca2+)o v erload,
protease activation, lipid accumulation etc) or activation
of harmful signaling pathways (e.g., kinases/phosphatases,
proteases, Bax/-Bid-mediated pathways etc.) occur, mito-
chondria undergo the MPT, a phenomenon that consists in
a sudden increase in IM permeability to small molecules.
MPT is a phenomenon ﬁrst studied in isolated beef heart
mitochondria in response to Ca2+ overload [16]. Thus, the
response of isolated mitochondria to doses of Ca2+ is a
nonspeciﬁc increase of the permeability of the IM, resulting
in entry of water and solutes, loss of ΔΨm, matrix swelling,
and simultaneous uncoupling of oxidative phosphorylation
(Figure 1). Of note, the doses of Ca2+ depend largely on
the tissue origin of mitochondria and the amount of Ca2+
present in the buﬀers. Ultimately, MPT is accompanied by
matrix swelling and OM ruptures as shown by transmission
electron microscopy [17–19]. This phenomenon can be
blocked by Ca2+ chelation, ATP, Mg2+,a n dc y c l o s p o r i nA
(CsA) in vitro as well as in vivo [20–22].
MPT can be followed experimentally by the loss of
absorbance of a suspension of isolated mitochondria by
spectrophotometry and by the loss of ΔΨm using suit-
able ﬂuorescent probes (e.g. tetramethylrhodamine methyl
ester (TMRM), rhodamine 123 (Rhod123), 5, 5 ,6 ,6  -
tetrachloro-1, 1 ,3 ,3  -tetraethylbenzimidazol-carbocyanine
iodide (JC-1)) [19, 23]. The main interests of the use of
isolated organelles are to monitor mitochondrial responses
that are directly induced by compounds independently of
other cellular compartments and the possibility to automate
the measure in the perspective of pharmacological studies
[19, 23].
One major pitfall is that, whereas isolation procedures
are believed to be nondestructive for liver and cell lines
mitochondria [24, 25], mitochondrial responses of isolated
mitochondria from skeletal muscle and heart that may rely
on the cell architecture are (obviously) lost [26].
Another pitfall is the cross-contamination of the mito-
chondrial fraction with other cellular compartments and
purity of preparations must be checked carefully. MPT can
also be measured by imaging with the ﬂuorescent probe
calcein in the presence of cobalt in living cell as various
as hepatocytes, astrocytes and cardiomyocytes [27–31]. The
principle is that calcein (molecular weight, 620Da) can
diﬀuse into the whole cell, whereas cobalt, a ﬂuorescence
quencher, cannot enter into the mitochondrial matrix and
diﬀuses into the rest of the cell. Thus, in physiological
conditions mitochondria appear ﬂuorescent and following
MPT,thequenchingofcalceinbycobalttriggersadecreasein
ﬂuorescence.Forinstance,HeLacellstreatedbythapsigargin,
a SERCA pump inhibitor or A23187, a Ca2+ ionophore
[32], undergo MPT as shown by a signiﬁcant decrease in
calcein ﬂuorescence due to IM permeabilization and cobalt
quenching [30]. MPT has also been monitored in whole
heart by 2-deoxy[3H]glucose entrapment technique [33].
Of note, the full demonstration that the process is
mediated by PTPC opening requires its inhibition by pre-
treatment of cells or isolated mitochondria by CsA, the well-
known cyclophilin D (CypD) ligand [20, 34]. Moreover,
silencing of CypD by siRNA to prevent the induction of
MPT is becoming mandatory in cellulo, since the genetic
d e m o n s t r a t i o nt h a tC y p Di sc r i t i c a lf o rM P Ta n dc e l ld e a t h
[35].Biochemistry Research International 3
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Figure 1: Scheme of mitochondrial alterations following mitochondrial membrane permeabilization (MMP). In this model, in response
to the opening of the permeability transition pore (PTPC; green and red ellipses, corresponding to ANT and VDAC resp.), swollen
mitochondria exhibit an increase in volume, a more translucide matrix with less cristae and a permeabilized outer membrane. Cytochrome c
and apoptosis-inducing factor (AIF) (blue circles and yellow squares), normally conﬁned into the intermembrane space, are released trough
ruptures in the outer membrane. The transmembrane inner potential (ΔΨm) is dissipated in response to the arrest of the function of the
respiratory complexes (I to V), which contributes to an inhibition of ATP biosynthesis. Altogether, these alterations are lethal, irreversible
and lead to cell death.
3. DirectMechanisms of MPT Inhibition
PTPC is deﬁned as a voltage-dependent polyprotein com-
plex, which in certain conditions might form a nonselec-
tive channel at contact sites between both mitochondrial
membranes [36, 37]. By deﬁnition, mitochondria contain all
the proteins necessary for MPT induction and then MPT
does not necessitate any neosynthesis. Since the initial PTPC
identiﬁcation by electrophysiology, the molecular identity of
thisporeanditsregulatorsisstillcontroversial[38–40].ANT,
VDAC and CypD, the three former PTPC candidates, have
their own functions, irrespective of their association within
PTPC or other putative polyprotein complexes such as the
ATPsynthasome[41]andBcl-2familymemberoligomers[3,
12].Thus,someoftheunknownmembersofPTPCmayhave
their own role in metabolism (e.g., kinase, peptidyl-prolyl
isomerase, deshydrogenase), transport (e.g., mitochondrial
carrier, channel) or structure (e.g., dynamic machinery,
cytoskeleton, AKAP proteins). This means that lethal MPT
needs a stimulation to occur and in pathophysiological con-
ditions, this is mainly achieved by Ca2+ and ROS. Whatever
its composition, the PTPC is a widespread phenomenon
occurring in many diseases. Although it has been the subject
of intense research and therapeutic developments in cancer
with the search for PTPC inducers [42], it has emerged
only recently as a promising target for cytoprotection in
various diseases such as neurodegenerative, cardiovascular
and metabolic diseases. PTPC can be modulated directly by a
large panel of pharmacological agents, by post-translational
modiﬁcations and by cooperation with other proteins that
may have a major impact on the cell life as discussed below.
3.1. Pharmacological Inhibition of PTPC. Using isolated
mitochondria from various sources, an impressive body
of literature reports that many molecules or compounds
modulate the PTPC in response to Ca2+,R O S ,o rad i s e a s e .
Thus, some compounds can activate MPT, whereas a more
limited number of them can prevent the opening of PTPC.
Some compounds have known mitochondrial targets such
as ANT, VDAC, CypD, and translocator protein 18kDa
(Table 1). To summarize, the most investigated inhibitor of
PTPC is CsA, which modulates CypD, as discussed below.
One example with future therapeutic applications is car-
diac ischaemia/reperfusion injury. During an acute myocar-
dial infarction (AMI), tissue injury occurring after reperfu-
sionrepresentsasigniﬁcantamountofthewhole,irreversible
damage. Ischaemia and reperfusion cause a wide array of
functional and structural alterations of mitochondria. Some
of these responses are directly under the control of the highly
conserved transcriptional complex HIF-1 and result from
a modulation in expression of genes involved in glycolysis,
glucose metabolism, mitochondrial function, cell survival,
apoptosis, and resistance to oxidative stress [43].
PTPC opening plays a crucial role in this speciﬁc
component of myocardial infarction. Strong support for this
concept has recently been provided by the reduced infarct
size observed in mice lacking CypD [35]. Thus targeting4 Biochemistry Research International
Table 1: List of mitochondrial permeability transition (MPT) inhibitors. CypD, Cyclophilin D; VDAC, voltage-dependent anion channel;
ANT, adenine nucleotide translocase; UQ, ubiquinone.
MPT inhibitor Target Model References
Cyclosporin A CypD binding with ANT In vivo, isolated mitochondria, cells [44, 45]
Sanglifehrin A CypD In vivo, isolated mitochondria, cells [46, 47]
Bongkrekic acid ANT Isolated mitochondria, cells [48–50]
ADP/ATP ANT Isolated mitochondria, in vitro [51, 52]
NADH/NAD+ VDAC Isolated mitochondria, in vitro [53–55]
DIDS VDAC Isolated mitochondria, in vitro,c e l l s [ 52–58]
glutamate VDAC Isolated mitochondria, in vitro [59–61]
Ro 68–3400 ANT or PiC, not VDAC1 Isolated mitochondria, in vitro [61–63]
UQ(0) ANT or PiC Isolated mitochondria, in vitro [64, 65]
S15176 unknown, in IM In vivo, isolated mitochondria [66, 67]
Sildenaﬁl unknown In vivo, isolated mitochondria [68]
Debio-025 CypD In vivo, isolated mitochondria [69]
TRO19622 VDAC, translocator protein
18kDa In vivo, isolated mitochondria [70]
Carbon monoxide ANT, unknown Isolated mitochondria, cells [71]
Antamanide CypD Isolated mitochondria, cells [72]
PTPC appears a relevant strategy to reduce ischaemic dam-
ages at reperfusion. A large body of evidence has shown that
it is possible to reduce infarct size and to protect the heart
after an infarct by a postconditioning or pharmacological
strategy. Brief episodes of myocardial ischemia-reperfusion
employed during reperfusion after a prolonged ischaemic
insult may attenuate the total ischaemia-reperfusion injury.
Recently, CsA has been shown to dramatically reduce infarct
size in many animal species and in human. Recent proof-of-
concept clinical trials support the idea that targeting MPT
by either coronary intervention postconditioning or CsA can
reduce infarct size and improve the recovery of contractile
function after reperfusion [21, 73]. Such a strategy was also
applied to ischaemia-reperfusion damages in other tissues
and cells like vascular endothelial cells [74], hepatocytes [75,
76],andneurons[77–79].Moreover,someattemptstotarget
CsA to the mitochondrial compartment by conjugation
to the lipophilic triphenylphosphonium cation proved to
be promising in cytoprotection from glucose and oxygen
deprivation in neurons [80], in cardiomyocytes [81], and in
other various organs [82].
3.2. Role of Mitochondrial Kinases to Prevent PTPC Opening.
Several protective signal pathways involving multiple kinases
have been shown to converge on mitochondria and the
PTPC[83]t opr omot ec ellsurvi val(Table 2).Forinstance,in
cardiomyocytes, pools of kinases such as Akt, protein kinase
C-ε (PKCε), extracellular-regulated kinases (ERK), glycogen
synthase kinase-3 beta (GSK-3β), and hexokinases (HK) I
and II, are localized in or on mitochondria in addition to the
cytosol. These mitochondria-associated protein kinases may
integrate cytosolic stimuli and in turn, enhance tolerance of
myocytes to injury.
M oreover ,systematicproteomicapproachesrevealedthat
some of these kinases might form hetero-oligomers with
putative components of the PTPC. Brieﬂy, GSK-3β and
HKs are directly responsible for inhibition of opening of
the PTPC and, thus, for myocyte protection from necrosis
[96]. As a result, postconditioning, which leads to GSK-3β
inhibition, allows the myocardial salvage from reperfusion
injury by modulating MPT [86]. In the context of anticancer
chemotherapy, β-adrenergic receptors (β-ARs) modulate
anthracycline response through crosstalk with multiple sig-
naling pathways. β2-ARs are cardioprotective during expo-
sure to oxidative stress induced by doxorubicin (DOX). DOX
cardiotoxicity is mediated in part through a Ca2+-dependent
triggering of MPT as clearly shown by a 41% reduction
of DOX-induced mortality by CsA [97]. β2-ARs activate
prosurvivalkinasesandattenuatemitochondrialdysfunction
caused by oxidative stress. Accordingly, the invalidation of
β2-ARs enhances cardiotoxicity via negative regulation of
survival kinases and enhancement of intracellular Ca2+,t h u s
predisposing the mitochondria to opening of the PTPC [97].
Moreover, in cancer cell lines, activation of mitochon-
drial ERK protects cancer cells from death through inhi-
bition of the MPT [88]. ERK inhibition enhanced GSK-
3β-dependent phosphorylation of the pore regulator CypD,
whereas GSK-3β inhibition protected from PTPC opening.
By diﬀerent molecular mechanisms, some kinases such
as creatine kinase (CK) and HK have also cytoprotective
eﬀects and prevent PTPC opening. Depending on the tissue,
which supports their expression, these kinases may be
cytoprotective via a role in energy transfer to metabolites
such as creatine and glucose (Table 2).
3.3. Stabilization of Mitochondrial Membrane Permeability
by Bcl-2 Family Members. The Bcl-2 family is composed of
more than 25 proteins implicated in the control of life-or-
deathdecision[98].Thisproteinfamilyhasbeenparticularly
studied in cancer, which led to the classiﬁcation of Bcl-2 andBiochemistry Research International 5
Table 2: List of kinases contributing to a closure of PTP via phosphorylation mechanisms or protein-protein interaction. HK, hexokinase,
CK, creatine kinase, PKG, protein kinase G, PKA, protein kinase A, PKC, protein kinase C, ERK, extracellular signal-regulated kinase, GSK3,
glucose-regulated kinase 3, PI3K, phosphoinositol3 kinase, and Akt/PKB, protein kinase B.
Kinase Eﬀect Target/pathway Model References
Akt/PKB,
PI3K Indirect GSK3 via PI3K or eNos/PKG
pathways Cells [84, 85]
GSK3 Direct VDAC, ANT, CypD Isolated mitochondria,
cells, in vivo, in vitro [8, 37, 86, 87]
ERK Indiret GSK3 via PI3K pathway Cells [85, 88]
PKA Direct VDAC Isolated mitochondria [89]
PKC epsilon Direct VDAC Isolated mitochondria, in
vivo [90]
PKG Direct Unknown Isolated mitochondria, in
vivo [91, 92]
CK Local regulation of ATP/creatine
pools Energetic metabolism CK-expressing tissues [93, 94]
HK Local regulation of glucose/ATP
pools Energetic metabolism Isolated mitochondria,
cells, in vitro [57, 74, 87, 95]
Bax as oncogenes and tumor-suppressors, respectively. Some
members (e.g., Bax/Bad proteins, BH3-only proteins) favor
apoptosis, whereas other members, such as Bcl-2 and Bcl-
XL, prevent apoptosis. Moreover, it has been shown that the
eﬀects of Bcl-2 family proteins on mitochondria in cancer
cells are linked to clinical responses to chemotherapy [99].
The cytoprotective mechanisms of Bcl-2 family members
are multiple and include direct mitochondrial eﬀects [3,
12]. Thus, Bcl-2 contributes to the stabilization of the
mitochondrial membrane permeability, inhibition of ΔΨm
loss and cytochrome c release and, at least in tumor
cells, to the stimulation of oxidative phosphorylation [100–
103]. Thus, direct protein-protein interactions between
Bcl-2 family members, but also with several constitutive
mitochondrial proteins such as ANT (IM), VDAC (OM), or
FoF1-ATP synthase (IM) have been evidenced [104]. Bcl-
2 cooperates directly with ANT, to prevent PTPC opening
and to inhibit cell death [101, 105, 106]. In addition, Bcl-2
blockstheCa2+-inducedchannelfunctionofANTandfavors
ADP/ATP translocase function, which positively impacts the
intracellular levels of ATP [107]. Similarly, Bcl-2 and Bcl-XL
directly interact with VDAC modulating its channel function
[108]. Bcl-XL would bind also to the mitochondrial F0F1-
ATP synthase and regulate metabolic eﬃciency in neurons
[104]. Accordingly, recombinant proteins of some members
of the Bcl-2 family directly modulate PTPC in isolated
mitochondria from various sources, that is, liver and cancer
cells[25,109].SomespeciﬁcregionsofBcl-2(e.g.,BH3,BH4
domains) are responsible for these eﬀects and as expected,
peptides corresponding to these regions proved to modulate
apoptosis in cellulo or in isolated mitochondria, again
indicating a direct targeting of mitochondria [25]. Finally, in
vivo, the BH4 domain of Bcl-XL exerts antiapoptotic eﬀects
and attenuates ischaemia/reperfusion injury through anti-
apoptotic mechanism in rat hearts [110, 111].
4.IndirectMechanisms,WhichLead to
anIncreasedResistance ofPTPC Opening
By deﬁnition, several indirect mechanisms may lead to
blockade of PTPC opening via modulation of ΔΨm,
mitochondrial mass regulation, redox state, fusion/ﬁssion
processes and calcium retention capacity. This may be due
to modiﬁcation in protein expression, in posttranslational
modiﬁcations and in their interactome, which consequently
aﬀect signaling pathways. Below, we will analyze three
indirect mechanisms of PTPC protection that have recently
been elucidated.
4.1. Anti-Oxidant Protection. Mitochondria are major sites
of ROS production, which may contribute to the develop-
ment of various diseases including cardiovascular diseases
and aging. Several studies have thus described the eﬀects
of antioxidant administration in the context of cardiac and
liver pathologies in mice [112]. It is widely admitted that
natural antioxidants such as resveratrol and curcumin have
beneﬁcial eﬀects against ischaemia/reperfusion damages to
mitochondria and cells in rat liver or heart [113, 114]. These
eﬀects are complex since resveratrol has been proposed to
have multiple intracellular targets such as AMPK, SIRT1 and
Nrf2, which can inﬂuence the transcriptome to increase the
anti-oxidant defense (e.g., catalase, GPx, and GCLC), and
other genes such eNOS and PGC1α, which favor an increase
in mitochondrial mass and bioenergetics and decrease in
apoptosis and inﬂammation (for review: [115]).
Resveratrol treatment exerts beneﬁcial protective eﬀects
on survival, endothelium-dependent relaxation, and cardiac
contractility and mitochondrial function, suggesting that
resveratrol or metabolic activators could be a relevant ther-
apy in hypertension-induced heart failure [116]. Similarly,
in the heart, curcumin another polyphenol with antioxidant6 Biochemistry Research International
properties showed cardioprotective eﬀects in catecholamine
induced cardiotoxicity through prevention of mitochondrial
damage, PTPC opening [117], and ventricular dysfunction
[118] and in protecting rat myocardium against ischaemic
insult by decreasing oxidative stress [119].
Another promising example of compound is MitoQ10,
an ubiquinone derivative, which is a mitochondria-targeted
antioxidant [120]. It has proven to be useful for protecting
endothelial function and attenuating cardiac hypertrophy in
stroke-prone hypertensive rats [121]. Moreover, MitoQ10
potently inhibits cocain-induced cardiac damage via a
restoration of oxygen consumption and a stabilization of
ROS levels, speciﬁcally in interﬁbrillar mitochondria [122].
However, when used on isolated cardiac mitochondria,
MitoQ10 can be enhanced in a dose-dependent-manner
MPT in the presence of the prooxidant tert-butyl hydoper-
oxide (t-BHP) and suboptimal doses of Ca2+ (Figure 2),
although it acts as an antioxidant on rat liver mitochondria
[123]. This underscores the duality of anti- and prooxidant
compounds, whose eﬀects can depend either on the dose,
the redox state of the cell, the tissue, and/or the mode
of administration. This probably explains, at least in part,
the failure of anti-oxidants to protect eﬃciently the heart
function in clinical trials, as recently reviewed in [124].
4.2. Estrogens Protection. Sex and gender inﬂuence the onset
and the progression of many human diseases, notably age-
related diseases. Thus, estrogens, mainly 17β-estradiol, may
have pleiotropic eﬀects depending on the tissue [125]. For
instance, certain cardiovascular diseases, such as myocardial
hypertrophy and heart failure, diﬀer clearly in their clinical
manifestation and prognosis between women and men
[126]. As a consequence, hormonal mechanisms underlying
sex and gender diﬀerences are currently under intense
investigation.
Animal and cellular models have been particularly
instrumental to better understand estrogen protection at the
level of mitochondria [127]. For instance, in cerebral cir-
culation, estrogens mediate an enhancement of vasodilator
capacity, suppression of vascular inﬂammation and increase
of mitochondrial eﬃciency [125, 128, 129]. This eﬀect is, at
least in part, due to an increase in mitochondrial biogenesis
via gene expression modulation [129]a n dad e c r e a s ei n
superoxide production [125]. Accordingly, chronic estrogen
treatment increases mitochondrial capacity for oxidative
phosphorylation while decreasing production of ROS. In
breast and lung cancer cells, long-term estradiol treatment
activatestranscriptionofNRF-1andincreasesmitochondrial
biogenesis [130].
Moreover, mitochondrial eﬀects on PTPC might be
mediatedindirectlybyestrogenreceptors,αandβ,present in
nucleus,plasmamembrane,endoplasmicreticulumandeven
mitochondria [131]. In the context of ischaemia-reperfusion
injury, it is widely admitted that estrogens protects from
myocardial damage via an inhibition of PTPC function.
Notably, estradiol may activate the signaling cascade which
involves Akt, NO synthase, guanylyl cyclase and protein
kinase G, which results in blockade of MPT-induced release
of cytochrome c from mitochondria, respiratory inhibition
and caspase activation [131]. As a result, estrogens eﬀects
aremultifactorial,mostlyindirect.Evenifsomeestrogen-like
moleculescanbeeﬀectiveonisolatedmitochondria,aprecise
target of estrogen within PTPC is still unknown [132].
Thus, intriguingly, estrogens may prevent Ca2+-induced
cytochrome c release in isolated heart mitochondria, but not
mitochondrial swelling [133].
Estrogens also protect from chemotherapy-induced car-
diomyopathy in ovariectomized rats. Again, eﬀects on the
anti-oxidant cellular defenses have been proposed as one of
the target mechanism of estrogen [134].
4.3. Exercise Protection. Exercise training has proven to be
beneﬁcial in chronic diseases including heart failure, obesity,
diabetes ormetabolic syndrome.Becauseendurancetraining
improves symptoms and quality of life and decreases mor-
tality rate and hospitalization, it is increasingly recognized
as a beneﬁcial practice for these patients. Adaptation to
endurance training mainly involves energetic remodeling
in skeletal and cardiac muscles [135]. The mechanisms
involved in the beneﬁcial eﬀects of exercise training are far
from being understood. Skeletal muscles adapt to repeated
prolonged exercise by marked quantitative and qualitative
changes in mitochondria. Endurance training promotes an
increase in mitochondrial volume density and mitochon-
drial proteins by activating mitochondrial biogenesis [136].
Exercise training decreases apoptotic processes, and protects
mitochondrial function from oxidative stress and other
cardiac insults [137, 138]. Exercise training results in a
reduced sensitivity to PTPC opening in heart mitochondria
and confers mitochondrial protection. Moreover, even acute
exercise protects against cardiac mitochondrial dysfunc-
tion, preserving mitochondrial phosphorylation capacity
and attenuating DOX-induced decreased tolerance to PTPC
opening [139]. Proposed mechanisms to explain the cardio-
protective eﬀects of exercise are mediated, at least partially,
by redox changes and include the induction of myocardial
heat shock proteins, improved cardiac antioxidant capac-
ity and/or elevation of other cardioprotective molecules
[137].
5. Conclusion and Open Questions
In the last decade, direct and indirect approaches to protect
mitochondrial functions via PTPC modulation have been
explored. However, it is still too early to decipher the most
eﬃcient strategies in term of cytoprotection. Nevertheless,
recent studies and research advances have propelled mito-
chondria on the scene front of new therapeutic strategies.
However, a contradiction emerges between the need to kill
tumor cells in cancer therapy and to protect other cells from
injuries. Even more worrying is the fact that many anticancer
therapies have mitochondrial toxicity that becomes dramatic
when highly oxidative nondividing cells like cardiomyocytes
are concerned. Indeed, mitochondria are the main target
when cardiotoxicity of anticancer drugs is concerned [44,
140]. Thus one challenging issue of cytoprotection directedBiochemistry Research International 7
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Figure 2: MitoQ10 stimulates MPT in isolated cardiac mitochondria. (a) MitoQ10 increases the mitochondrial swelling induced by an
oxidant stress. Mitochondria (25μg of proteins) have been pretreated by the indicated doses of MitoQ10 and treated by 50μMt -B H P+
10μMC a
2+. Absorbance at 540nm has been registered for 60min at 37◦C. (b) MitoQ10 increases the mitochondrial depolarization induced
by an oxidant stress. Mitochondria (25μg of proteins) have been loaded with 2μM Rhodamine 123, pretreated by the indicated doses of
MitoQ10, and treated by 50μMt - B H P+1 0μMC a
2+. Fluorescence has been registered for 60min at 37◦C.
to mitochondria would be to uncover new molecules or
treatments that would selectively target cancer cells without
aﬀecting cardiac mitochondria. This should stimulate new
studies devoted to increase our basic knowledge of the
mechanisms and the tissue speciﬁcity of PTPC opening and
mitochondrial function. At the same time, this will open the
possibility to search for new drugs with tissue-speciﬁc eﬀects
on mitochondria. Finally, another challenge that basic and
clinicalresearchwillfaceinthefutureisthenotionofsexand
gender inﬂuence that might be decisive for the treatment of
many severe diseases.
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